US FDA Approves Bristol Mayers Squibb Cardio Drug ‘Camzyos’
The Food and Drug Administration (FDA) of the United States has given the approval to Camzyos of Bristol Myers Squibb for the purpose of treating the symptomatic obsutructive hypertrophic cardiomyopathy (obstructive HCM). The drug, which is formerly known as mavacamten, has been representing a potential and important addition to the cardiovascular stable, which is needing […]
Continue Reading